Literature DB >> 12324565

Low-dose heparin for severe sepsis.

Bruce L Davidson, William H Geerts, Anthonie W A Lensing.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12324565     DOI： 10.1056/NEJM200209263471316

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  15 in total

1.  How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? A Bayesian design.

Authors:  Andre C Kalil; Junfeng Sun
Journal:  Intensive Care Med       Date:  2008-05-27       Impact factor: 17.440

2.  Regulation of PMA-induced MUC5AC expression by heparin in human bronchial epithelial cells.

Authors:  Qi Li; Rui Xia Lei; Xiang Dong Zhou; Victor P Kolosov; Juliy M Perelman
Journal:  Mol Cell Biochem       Date:  2011-10-05       Impact factor: 3.396

Review 3.  Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome.

Authors:  Magda Cepkova; Michael A Matthay
Journal:  J Intensive Care Med       Date:  2006 May-Jun       Impact factor: 3.510

Review 4.  [Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin].

Authors:  M Angstwurm; J Hoffmann; H Ostermann; L Frey; M Spannagl
Journal:  Anaesthesist       Date:  2009-02       Impact factor: 1.041

Review 5.  Activated protein C in sepsis: the promise of nonanticoagulant activated protein C.

Authors:  Hartmut Weiler; Wolfram Ruf
Journal:  Curr Opin Hematol       Date:  2008-09       Impact factor: 3.284

Review 6.  Advances in sepsis therapy.

Authors:  Thomas Glück; Steven M Opal
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Syndecan-1 shedding facilitates the resolution of neutrophilic inflammation by removing sequestered CXC chemokines.

Authors:  Kazutaka Hayashida; William C Parks; Pyong Woo Park
Journal:  Blood       Date:  2009-07-28       Impact factor: 22.113

8.  Syndecan-1 is an in vivo suppressor of Gram-positive toxic shock.

Authors:  Kazutaka Hayashida; Ye Chen; Allison H Bartlett; Pyong Woo Park
Journal:  J Biol Chem       Date:  2008-05-22       Impact factor: 5.157

9.  Antithrombosis Trials: Should we test therapeutic heparin adjusted based on activated partial thromboplastin time in septic shock?

Authors:  Amisha V Barochia; Yan Li; Xizhong Cui; Daniel A Sweeney; Charles Natanson; Peter Q Eichacker
Journal:  Crit Care Med       Date:  2009-04       Impact factor: 7.598

Review 10.  Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa.

Authors:  Todd W Rice
Journal:  Vasc Health Risk Manag       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.